Bacteriotherapy using fecal flora - Toying with human motions

被引:204
作者
Borody, TJ
Warren, EF
Leis, SM
Surace, R
Ashman, O
Siarakas, S
机构
[1] Probiot Therapy Res Ctr, Sydney, NSW 2046, Australia
[2] Concord Repatriat Gen Hosp, Dept Microbiol, Sydney, NSW 2046, Australia
[3] Ctr Digest Dis, Sydney, NSW 2046, Australia
关键词
feces; Clostridium difficile; intestinal diseases; probiotics; therapy;
D O I
10.1097/01.mcg.0000128988.13808.dc
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The intestinal flora may play a key role in the pathogenesis of certain gastrointestinal (GI) diseases. Components of bowel flora such as Lactobacillus acidophilus and Bifidobacterium bifidus have long been used empirically as therapeutic agents for GI disorders. More complex combinations of probiotics for therapeutic bacteriotherapy have also recently become available, however the most elaborate mix of human-derived probiotic bacteria is, by definition, the entire fecal flora. Fecal bacteriotherapy uses the complete normal human flora as a therapeutic probiotic mixture of living organisms. This type of bacteriotherapy has a longstanding history in animal health and has been used sporadically against chronic infections of the bowel, especially as a treatment of last resort for patients with severe Clostridium difficile syndromes including recurrent diarrhea, colitis, and pseudomembranous colitis. Encouraging results have also been observed following infusions of human fecal flora in patients with inflammatory bowel disease, irritable bowel syndrome, and chronic constipation. The therapeutic use of fecal bacteriotherapy is reviewed here and possible mechanisms of action and potential applications explored. Published reports on fecal bacteriotherapy are few in number, and detail the results of small uncontrolled open studies and case reports. Nevertheless, given the promising clinical responses, formal research into fecal bacteriotherapy is now warranted.
引用
收藏
页码:475 / 483
页数:9
相关论文
共 81 条
[1]   Recurrent Clostridium difficile colitis:: Case series involving 18 patients treated with donor stool administered via a nasogastric tube [J].
Aas, J ;
Gessert, CE ;
Bakken, JS .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) :580-585
[2]   Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea [J].
Alfa, MJ ;
Kabani, A ;
Lyerly, D ;
Moncrief, S ;
Neville, LM ;
Al-Barrak, A ;
Harding, GKH ;
Dyck, B ;
Olekson, K ;
Embil, JM .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (07) :2706-2714
[3]  
ANDREWS PJ, 1992, EUR J GASTROEN HEPAT, V4, P245
[4]  
[Anonymous], PROBIOTICS PREBIOTIC
[5]  
[Anonymous], CAN J GASTROENTE SSA
[6]   Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France [J].
Barbut, F ;
Lalande, V ;
Burghoffer, B ;
Thien, HV ;
Grimprel, E ;
Petit, JC .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (06) :2079-2083
[7]   ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITIS DUE TO TOXIN-PRODUCING CLOSTRIDIA [J].
BARTLETT, JG ;
CHANG, TW ;
GURWITH, M ;
GORBACH, SL ;
ONDERDONK, AB .
NEW ENGLAND JOURNAL OF MEDICINE, 1978, 298 (10) :531-534
[8]  
BENNET JD, 1989, LANCET, V1, P164
[9]   TREATMENT OF RECURRENT CLOSTRIDIUM-DIFFICILE COLITIS WITH LACTOBACILLUS GG [J].
BILLER, JA ;
KATZ, AJ ;
FLORES, AF ;
BUIE, TM ;
GORBACH, SL .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1995, 21 (02) :224-226
[10]   BOWEL-FLORA ALTERATION - A POTENTIAL CURE FOR INFLAMMATORY BOWEL-DISEASE AND IRRITABLE BOWEL SYNDROME [J].
BORODY, TJ ;
GEORGE, L ;
ANDREWS, P ;
BRANDL, S ;
NOONAN, S ;
COLE, P ;
HYLAND, L ;
MORGAN, A ;
MAYSEY, J ;
MOOREJONES, D .
MEDICAL JOURNAL OF AUSTRALIA, 1989, 150 (10) :604-604